In the study of communities in Massachusetts with high numbers of opioid overdose deaths, implementation of overdose education and naloxone distribution (OEND) were associated with a significant reduction in opioid overdose death rates.
In a study of communities in Massachusetts with high numbers of opioid overdose deaths, implementation of overdose education and naloxone distribution (OEND) were associated with a significant reduction in opioid overdose death rates.
The study was led by researchers at Boston Medical Center (BMC), Boston University Schools of Medicine (BUSM) and Public Health (BUSMPH) in collaboration with the Massachusetts Department of Public Health (MDPH) and published in the British Medical Journal.
In the United States, increases in fatal overdose since the mid-1990s have been fueled by the growth in prescriptions for opioid analgesics, according to the study. Drug overdose has surpassed motor vehicle crashes to be the leading cause of death by injury in the United States. Overdose is also a major cause of death in Canada, Europe, Asia, and Australia. Opioid-related emergency department visits and hospital admissions have increased over the same period. In Massachusetts, since 2005, annual opioid-related overdose deaths have exceeded motor vehicle deaths.
OEND is a community-based intervention that educates people at risk for overdose and potential bystanders on how to prevent, recognize and respond to an overdose. It also equips these individuals with a naloxone rescue kit. Naloxone, which may be administered by injection or by nasal spray, is a safe and effective antidote that reverses the life-threatening effects of an opioid overdose.
Between 2006 and 2009, Massachusetts OEND programs in 19 communities trained 2,912 potential bystanders who reported 327 rescues. Compared with no implementation, both low and high implementation of OEND were associated with lower rates of opioid related overdose deaths, when adjusted for demographics, addiction treatment utilization, and doctor shopping. Opioid overdose related visits to emergency departments and hospital admission rates did not differ significantly in communities with low versus high OEND implementation.
Study lead author Alexander Walley, MD, MSc, an attending physician in general internal medicine at BMC, and colleagues conducted an interrupted time series analysis of rates of opioid related deaths from overdose and acute care utilization from 2002 to 2009 that compared community-year strata with high and low rates of OEND implementation to those with no OEND implementation. Poisson regression models were adjusted for community-level demographics and substance use-related factors.
“OEND is an innovative, community-based program deployed in many settings that has not been examined in controlled studies,” Dr Walley told Formulary. “This study provides observational evidence that OEND is an effective public health intervention to address increasing mortality from opioid overdose by training potential bystanders to prevent, recognize, and respond to opioid overdoses. OEND implementation seemed to have a dose-related impact where the higher the cumulative rate of OEND implementation, the greater the reduction in death rates.”
This study provides strong support for the public health agency policy and community-based organization practice to implement and expand OEND programs as a key way to address the opioid overdose epidemic, according to Dr Walley. “Two features of the Massachusetts OEND programs that supported broad implementation include the use of an nasal naloxone delivery device and the use of a standing order issued by the health department, which allowed non-medical personnel to deliver OEND,” he said. “These features may enable broader implementation with greater impact as more communities implement OEND.”
“Opioid overdose death rates were reduced in communities where OEND was implemented,” Dr Walley said. “This study provides observational evidence that by training potential bystanders to prevent, recognize, and respond to opioid overdoses, OEND is an effective intervention.” â
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.